eos884448
mAbexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 18, 2020 (NCT04335253)
Timeline
Indications
Mechanism of action
TIGIT antagonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05565378 | Phase 2 | Oct 14, 2022 | GlaxoSmithKline, iTeos Therapeutics |
| NCT05289492 | Phase 1/Phase 2 (Phase 2) | May 1, 2022 | Bristol-Myers Squibb, GlaxoSmithKline, iTeos Therapeutics |
| NCT05277051 | Phase 1 | Mar 22, 2022 | GlaxoSmithKline |
| NCT05060432 | Phase 1/Phase 2 (Phase 2) | Sep 6, 2021 | iTeos Therapeutics |
| NCT04335253 | Phase 1 | Feb 18, 2020 | iTeos Therapeutics |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| iTeos Therapeutics | For profit | 4 | 3 | 2 | 2020 |
| GlaxoSmithKline | For profit | 3 | 2 | 2 | 2022 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1